Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unnamed Lilly "Mirror Fund" Acquires First Two Compounds

This article was originally published in The Pink Sheet Daily

Executive Summary

The acquisitions of two drug candidates - one from Lilly, one from a university - are the first in the pharma's latest scheme to share risk with VCs.
Advertisement

Related Content

Latest Pharma-VC Experiment: Arteaus Gets $18M For Migraine Drug Licensed From Lilly
Some VCs Have Miles To Go While Others Have Burned What's In The Tank
Blood Clot Risk Causes Lilly, Bristol To Halt Enrollment In Erbitux Follow-On Trial
Pfizer Signs Up Seven New York Institutions To Create Biomedical Discovery Engine
Pfizer Signs Up Seven New York Institutions To Create Biomedical Discovery Engine
As Pfizer And UCSF Tighten Ties, More Deals With Academia Could Follow
Inside Lilly Research Laboratories: A Discussion With Jan Lundberg
Pharma: Serious About Change?
Lilly To Cease Development Of Alzheimer's Drug: A Blow To The Amyloid Hypothesis?
Lilly's Chorus Experiment

Topics

Advertisement
UsernamePublicRestriction

Register

PS071833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel